Key result
Dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors are being evaluated in this network meta-analysis protocol for cardiovascular disease, which contains no results.
Key points are not available for this paper at this time.
No results yet to guide therapy; protocol leaves open network comparisons of these agents in CVD.
like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis (Protocol).
No takes yet. Share an insight, caveat, or question.
Kanie et al. (2020) studied this question. Dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors are being evaluated in this network meta-analysis protocol for cardiovascular disease, which contains no results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: